Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Maltoni

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Chemotherapy (Florence, Italy)|August 1, 1994
A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferonR Ridolfi, R Maltoni, A Riccobon, et al.
Breast Cancer Research and Treatment|March 1, 1997
Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective studyD Amadori, A Volpi, R Maltoni, et al.
Cancer Immunology, Immunotherapy : CII|July 22, 1998
Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patientsR Ridolfi, E Flamini, A Riccobon, et al.
Biomed Research International|September 23, 2014
New biomarkers to predict the evolution of in situ breast cancersS Bravaccini, M M Tumedei, E Scarpi, et al.
Gynecologic Oncology|June 1, 1997
Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord OvestM Bruzzone, A Rubagotti, A Gadducci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡P Conte, A Frassoldati, G Bisagni, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Chemotherapy (Florence, Italy)|August 1, 1994
A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferonR Ridolfi, R Maltoni, A Riccobon, et al.
Breast Cancer Research and Treatment|March 1, 1997
Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective studyD Amadori, A Volpi, R Maltoni, et al.
Cancer Immunology, Immunotherapy : CII|July 22, 1998
Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patientsR Ridolfi, E Flamini, A Riccobon, et al.
Biomed Research International|September 23, 2014
New biomarkers to predict the evolution of in situ breast cancersS Bravaccini, M M Tumedei, E Scarpi, et al.
Gynecologic Oncology|June 1, 1997
Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord OvestM Bruzzone, A Rubagotti, A Gadducci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡P Conte, A Frassoldati, G Bisagni, et al.
Pageof 2